Catalogue Number: AB04214-30.11-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 0.5 mg |
| Host name: | |
| Clone: | scFv59 |
| Isotype: | |
| Immunogen: | The original antibody was isolated from a human scFv phage library by screening against Abeta1-42. |
| Application: | ELISA, WB, IHC, InVivoA, ThT |
APP
351
P05067
Purified
Recombinant Monoclonal
Aβ; Abeta; Amyloid-beta precursor protein; APP; ABPP; APPI; Alzheimer disease amyloid A4 protein homolog; Alzheimer disease amyloid protein; Amyloid precursor protein; Amyloid-beta (A4) precursor protein; Amyloid-beta A4 protein; Cerebral vascular amyloid peptide (CVAP); PreA4; Protease nexin-II (PN-II)
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
The scFv version of this antibody demonstrated the highest ELISA titer for Aβimmunoreactivity against Aβ1-42, and its specificity for oligomeric and fibrillar/aggregated Aβ was demonstrated in a WB. The scFv version of this antibody reacted with amyloid beta deposits in brain sections from a Tg2576 mouse and in skeletal muscle sections from a Tg13592 mouse, as observed via IHC. The scFv version of this antibody was used to inhibit the formation of Aβ fibril formation in vitro as demonstrated in a Thioflavin T assay. This inhibition contributed to the amelioration of Aβ cytotoxicity as was shown in vitro in an MTT assay; cell viability increased from 45.2 +/- 0.78% to 58.8 +/- 5.45% (P = 0.069) in the presence of scFv59. Furthermore, Tg2576 mice subjected to scFv59 injection in the hippocampus and cortex had fewer diffuse and fibrillar Aβ deposits in those areas than Tg2576 mice injected with PBS (Fukuchi et al., 2006; PMID: 16630540). Vascular amyloid was also stained by scFv59 (Fukuchi et al., 2006; PMID: 16766200).
This is a reformatted human scFv antibody, based on the original human scFv format, created for improved compatibility with existing reagents, assays and techniques.